Psyence Biomedical to Issue Shares for $5M PsyLabs Investment, Resulting in Near 100% Dilution and 49.98% PsyLabs Ownership

summarizeSummary

Psyence Biomedical Ltd. announced PsyLabs exercised a $5 million put option, leading to the issuance of 1.15 million PBM shares and nearly 100% dilution for existing shareholders, with PsyLabs gaining a 49.98% stake.

check_boxKey Events · Financing and Capital Events · PBM

• Put Option Exercised

  PsyLabs exercised its $5 million put option, requiring Psyence Biomedical to subscribe for PsyLabs shares in a non-cash transaction.

• Significant Share Issuance

  Psyence Biomedical will issue 1,146,159 common shares to PsyLabs, calculated using a 30-day VWAP of $4.36 per share.

• Extreme Dilution

  This issuance represents nearly 100% dilution to existing shareholders, based on the prior outstanding share count of 1,147,148 common shares.

• Control Shift

  Following the issuance, PsyLabs will beneficially own approximately 49.98% of Psyence Biomedical's issued and outstanding common shares.

auto_awesomeAnalysis · PBM · Life Sciences

This filing confirms the exercise of a previously disclosed put option by PsyLabs, resulting in a highly dilutive share-for-share exchange. The issuance of 1.15 million common shares to PsyLabs, based on a $4.36 VWAP, will nearly double the outstanding share count and grant PsyLabs a significant 49.98% ownership stake. While the company states this strengthens a strategic relationship and secures supply, the extreme dilution and substantial shift in control are significantly negative for existing shareholders. The transaction value of $5 million is nearly double the company's current market capitalization, underscoring the magnitude of this capital event.